NOC
44
-3
GOOGL
66
-6
PEG
50
-5
OI
25
-5
O
15
-2
AMG
52
-3
SPG
53
-5
TROW
40
-8
WMB
55
-4
PWR
67
-3
SIG
50
-4
AVB
57
-2
FCX
45
-2
HBAN
51
-3
ORLY
56
-9
FTI
69
-7
NEM
42
-2
EL
30
-4
RF
45
-6
FRT
43
-2
NOC
44
-3
GOOGL
66
-6
PEG
50
-5
OI
25
-5
O
15
-2
AMG
52
-3
SPG
53
-5
TROW
40
-8
WMB
55
-4
PWR
67
-3
SIG
50
-4
AVB
57
-2
FCX
45
-2
HBAN
51
-3
ORLY
56
-9
FTI
69
-7
NEM
42
-2
EL
30
-4
RF
45
-6
FRT
43
-2
Financhill
Back

Monopar Therapeutics Quote, Financials, Valuation and Earnings

This Tech Company Grew 32,481%...

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
75

MNPR
Monopar Therapeutics

Last Price:
30.15
Seasonality Move:
35.55%

7 Day Trial

ALL ACCESS PASS

$ 7

This is an offer you won't want to refuse...

Hurry. Don't miss these two trades.

Monopar Therapeutics Price Quote

$30.15
-0.53 (-1.73%)
(Updated: December 18, 2024 at 10:00 AM ET)

Monopar Therapeutics Key Stats

Buy
75
Monopar Therapeutics (MNPR) is a Buy
Day range:
$26.00 - $31.96
52-week range:
$1.55 - $38.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
32.73%
Volume:
109.4K
Avg. volume:
113.3K
1-year change:
1564.23%
Market cap:
$161.9M
Revenue:
$0
EPS:
$-1.99

How Much Does Monopar Therapeutics Make?

Data Unavailable

Is Monopar Therapeutics Growing As A Company?

Data Unavailable

Monopar Therapeutics Stock Price Performance

What Is Monopar Therapeutics 52-Week High & Low?

Monopar Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Monopar Therapeutics?

Is Monopar Therapeutics Cash Flow Positive?

  • What Is MNPR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$6M
  • What Is Monopar Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $3.5M
  • What Is Monopar Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $3M

Monopar Therapeutics Return On Invested Capital

Data Unavailable

Monopar Therapeutics Earnings Date & Stock Price

Monopar Therapeutics Competitors

Monopar Therapeutics Dividend Yield

Monopar Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -58.12%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 27.33
Downside from Last Price: -10.91%

Major Shareholders

  • How many MNPR shares are owned by institutional investors?
    1.7M MNPR shares are owned by institutional investors
  • How many MNPR shares are owned by insiders?
    515K MNPR shares are owned by insiders